calbucks, i think you are right. not to water down the value that hparch did in getting us the information- excellent dd work btw. Pulitzer? very close!... maybe a michelangelo award for getting us better color of some of the work by the company... k
how about a new Chief Scientific Officer instead... CSO... since IDRA is a clinical-stage biotech...
Chief Medical Officer implies they have a line of approved drugs.. and that the CMO oversees the safe, effective and appropriate use of these medicines.
cmhe, you might just be surprised someday... k
okay, okay, mudbug you win... there's no sense having this spat with you... we are on the same side after all... I luv you man... peace... k
Dudes! I don't wanna see anyone in trouble. For a publicly traded company to selectively disseminate information is frowned upon by the SEC. It gives advantage to 'people in the know', disparaging those in the dark. Trading with 'inside information' is a crime. all imho... k
cmhe, some people have 'where's the beef attitude'. I think it is there. 95% of the company is now held by institutions and insiders. It leads me to believe that there is interest in MNTA. I bought in and am nearing 10k. I post this so that you can say i told you so when it goes down, i'm fine with that... i believe in the company and i am taking the risk... 'cause, only a real risk can test the reality of a belief... k
two questions please....
seeing that there seem to be new information here, was selective dissemination of information came to mind?... did he give you the usual caveat as when they do CCs?.. thanks... k
it will be approved by SEptember...sooner if FDA approves... teva's patent will expire then... and no one but us that is taking advantage... we will be anonymous millionaires!.... :) k
the management agrees that it is undervalued... they are saying that the ruling on Copaxone is holding MNTA back... without this, the company should rise to the levels of the bio-similar companies..
if approved... it will mean that it works... it will get a breakthrough designation...it will work for breast, ovarian, and cholorectal cancer, and many other indications... $200?... I think north of $500 easy... imo... k
over $250 Billion in the year 2020... k
80% powered to detect a 50% improvement for overall survival.... they don't have to get to 50% survival benefit for it to be a clinically meaningful result... this trial is the same design that you would use for a phase 3 trial... it is a pivotal trial, one that can be used as a registration study.. k
I think it's yahoo policy... no links... they'll delete your post if you include them...
i did not follow your link right away because i was busy. when i came back it was gone. but i typed pfe breast cancer drug breakthrough designation and there it was... palbociclib... k
nice one indeed jb!... debentures rolled into revolving credit...
btw... idra is now below your buy in point did you nibble?... i'm staying on the sideline for now... k
I've clearly posted with a caveat - 'so they say'... but the quote is from Ganesh V. Kaundinya, Ph.D. ... he says and let me paraphrase... because of advancement of science, they've learned that there are different cells that are impacted all the way down to the fibroblast, even to osteoclast, bone development, chondrocyte etc... then he says, and preclinical models are not good in predicting.... a mouse and a monkey and any of these preclinical models are really complex organism... that can be used and is good for comparison... (Dr. Kaundinya was a member of the MIT faculty where he pioneered research in the areas of analytical techniques for complex molecules and extracellular matrix regulation of cell biology. He also served as the Director of Bioinformatics for the Consortium for Functional Glycomics, a multi-milliondollar NIH initiative to study the role of complex sugars in biology.)...
.... aloha k
tony... dude!... I've got your resolve when I was in Vinnie's VPHM... they've drop the price one day and I show low six figures in paper profits gone... up in smoke!... I held on... k